Citations to this article
Benjamin Y. Jin, … , Cornelia L. Trimble, Christian S. Hinrichs
Published April 19, 2018
Citation Information: JCI Insight. 2018;3(8):e99488. https://doi.org/10.1172/jci.insight.99488.
Citation Information: JCI Insight. 2018;3(8):e99488. https://doi.org/10.1172/jci.insight.99488.
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Abstract
T cell receptor (TCR) T cell therapy is a promising cancer treatment modality. However, its successful development for epithelial cancers may depend on the identification of high-avidity TCRs directed against tumor-restricted target antigens. The human papillomavirus (HPV) E7 antigen is an attractive therapeutic target that is constitutively expressed by HPV+ cancers but not by healthy tissues. It is unknown if genetically engineered TCR T cells that target E7 can mediate regression of HPV+ cancers. We identified an HPV-16 E7-specific, HLA-A*02:01-restricted TCR from a uterine cervix biopsy from a woman with cervical intraepithelial neoplasia. This TCR demonstrated high functional avidity, with CD8 coreceptor–independent tumor targeting. Human T cells transduced to express the TCR specifically recognized and killed HPV-16+ cervical and oropharyngeal cancer cell lines and mediated regression of established HPV-16+ human cervical cancer tumors in a mouse model. These findings support the therapeutic potential of this approach and established the basis for an E7 TCR gene therapy clinical trial in patients with metastatic HPV+ cancers (NCT02858310).
Authors
Benjamin Y. Jin, Tracy E. Campbell, Lindsey M. Draper, Sanja Stevanović, Bianca Weissbrich, Zhiya Yu, Nicholas P. Restifo, Steven A. Rosenberg, Cornelia L. Trimble, Christian S. Hinrichs
Total citations by year
Citation information
Citations to this article in year 2023 (21)
| Title and authors | Publication | Year |
|---|---|---|
|
Tumor cells fail to present MHC-II restricted epitopes derived from oncogenes to CD4+ T cells
Spencer Brightman, Martin Naradikian, Rukman Thota, Angelica Becker, Leslie Montero, Milad Bahmanof, Ashmitaa Premlal, Jason Greenbaum, Bjoern Peters, Ezra Cohen, Aaron Miller, Stephen Schoenberger |
JCI Insight | 2023 |
|
Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond
Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, Yannaki E |
HemaSphere | 2023 |
|
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Baulu E, Gardet C, Chuvin N, Depil S |
Science Advances | 2023 |
|
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination
Mühlenbruch L, Abou-Kors T, Dubbelaar ML, Bichmann L, Kohlbacher O, Bens M, Thomas J, Ezić J, Kraus JM, Kestler HA, von Witzleben A, Mytilineos J, Fürst D, Engelhardt D, Doescher J, Greve J, Schuler PJ, Theodoraki MN, Brunner C, Hoffmann TK, Rammensee HG, Walz JS, Laban S |
British Journal of Cancer | 2023 |
|
EDA-E7 Activated DCs Induces Cytotoxic T Lymphocyte Immune Responses against HPV Expressing Cervical Cancer in Human Setting
Feng J, Liu Y, Zhuang N, Chai Z, Liu L, Qian C, Li J, Shan J |
Human vaccines | 2023 |
|
The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy
Starska-Kowarska K |
Cancers | 2023 |
|
Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer
Saba NF, Pamulapati S, Patel B, Mody M, Strojan P, Takes R, Mäkitie AA, Cohen O, Pace-Asciak P, Vermorken JB, Bradford C, Forastiere A, Teng Y, Wieland A, Ferlito A |
Cancers | 2023 |
|
T cell immunotherapy for cervical cancer: challenges and opportunities
Yu L, Lanqing G, Huang Z, Xin X, Minglin L, Fa-hui L, Zou H, Min J |
Frontiers in immunology | 2023 |
|
Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer
Sievers C, Craveiro M, Friedman J, Robbins Y, Yang X, Bai K, Nguyen A, Redman JM, Chari R, Soon-Shiong P, Schlom J, Gulley J, Allen CT |
Cancer Cell | 2023 |
|
Immunotherapy in Anal Cancer.
Dhawan N, Afzal MZ, Amin M |
Current oncology (Toronto, Ont.) | 2023 |
|
N-Acetyl-L-Cysteine Reduces Cervical Carcinogenesis by Promoting Apoptosis.
Guo W, Jing W |
Drugs in R & D | 2023 |
|
The Tumor-Specific Immune Landscape in HPV+ Head and Neck Cancer
Conarty JP, Wieland A |
Viruses | 2023 |
|
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation
Cieniewicz B, Bhatta A, Torabi D, Baichoo P, Saxton M, Arballo A, Nguyen L, Thomas S, Kethar H, Kukutla P, Shoaga O, Yu B, Yang Z, Fate M, Oliveira E, Ning H, Corey L, Corey D |
Molecular Therapy | 2023 |
|
Multi-tiered approach to detect autoimmune cross-reactivity of therapeutic T cell receptors
Ishii K, Davies JS, Sinkoe AL, Nguyen KA, Norberg SM, McIntosh CP, Kadakia T, Serna C, Rae Z, Kelly MC, Hinrichs CS |
Science Advances | 2023 |
|
A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics.
Álvarez Freile J, Qi Y, Jacob L, Lobo MF, Lourens HJ, Huls G, Bremer E |
Frontiers in immunology | 2023 |
|
Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment.
Silva AJD, Moura IA, Gama MATMD, Leal LRS, Pinho SS, Espinoza BCF, Santos DLD, Santos VEP, Sena MGAM, Invenção MDCV, Macêdo LS, França Neto PL, Freitas AC |
Human vaccines | 2023 |
|
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, Hu W |
Molecular Cancer | 2023 |
|
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T, Yoshizato T, Rustad EH, Nielsen MM, Bollineni RC, Tran TT, Delic-Sarac M, Gjerdingen TJ, Douvlataniotis K, Laos M, Ali M, Hillen A, Mazzi S, Chin DW, Mehta A, Holm JS, Bentzen AK, Bill M, Griffioen M, Gedde-Dahl T, Lehmann S, Jacobsen SE, Woll PS, Olweus J |
Nature cancer | 2023 |
|
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.
Klebanoff CA, Chandran SS, Baker BM, Quezada SA, Ribas A |
Nature reviews. Drug discovery | 2023 |
|
Epigenetic and Genetic Keys to Fight HPV-Related Cancers
Folliero V, Dell\u2019Annunziata F, Chianese A, Morone MV, Mensitieri F, Di Spirito F, Mollo A, Amato M, Galdiero M, Dal Piaz F, Pagliano P, Rinaldi L, Franci G |
Cancers | 2023 |
|
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors.
Johnston AC, Alicea GM, Lee CC, Patel PV, Hanna EA, Vaz E, Forjaz A, Wan Z, Nair PR, Lim Y, Chen T, Du W, Kim D, Nichakawade TD, Rebecca VW, Bonifant CL, Fan R, Kiemen AL, Wu PH, Wirtz D |
bioRxiv : the preprint server for biology | 2023 |
